As the world's largest independent blood and plasma donation center operator, ImmunoTek invites the Morristown community to visit the facility to learn more about plasma donations and how they can positively impact others.
By removing the red and white blood cells from the blood, what remains is the golden liquid called plasma.
Blood-plasma helps create medicines and plasma-based therapies that treat patients with various diseases and disorders, including shock and burn patients, bleeding disorders, transplant patients, those suffering from autoimmune diseases, and many others.
Scientists cannot synthesize blood-plasma, so centers like the new ImmunoTek Plasma in Morristown are vital to keeping up with the worldwide demand for plasma.
The United States provides 2/3 of the world's plasma, and demand increases by 6% - 8% yearly.
To be eligible to donate plasma, in-house medical professionals conduct a medical screening, medical history review, and physical exam. Donating plasma is much like making a blood donation.
A safe, sterile, automated process called plasmapheresis separates plasma from the blood and returns the remaining red blood cells to the donor. Donors can give plasma up to twice a week.
ImmunoTek Plasma's new Morristown location is at 3004 W Andrew Johnson Hwy and will operate Tuesday – Saturday.
Walk-in donors are welcome for their first donation; subsequent donations are only by appointment.
Operated by ImmunoTek Bio Centers LLC, ImmunoTek Plasma provides a chance for plasma donors to positively impact the lives of patients who rely on plasma-based therapies while being compensated for their time.
ImmunoTek Bio Centers is the world's largest independent plasma collection center operator.
Roivant to announce Q3 2026 financial results
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
Physiomics secures follow-on UK contract for Phase 2 study support
Amgen's UPLIZNA receives US FDA approval
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
AstraZeneca to invest USD2bn in major Maryland manufacturing expansion
European Commission approves Celltrion's Remsima IV liquid formulation
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Vascarta and CUNY report positive preclinical results in glioblastoma treatment